Navigation Links
Dendreon Announces Presentation of PROVENGE Data at the American Society of Clinical Oncology Annual Meeting
Date:5/20/2010

SEATTLE and CHICAGO, May 20 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced the upcoming presentation of data from integrated analyses of three Phase 3 PROVENGE® (sipuleucel-T) clinical trials of an autologous cellular immunotherapy in advanced prostate cancer, to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago on Monday, June 7 at 8:00 a.m. CT.

"With the recent FDA approval of PROVENGE for asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer, patients now have a new treatment option available that prolongs survival," said Daniel P. Petrylak, M.D., program director of the Genitourinary Oncology Section in the Division of Hematology/Oncology at Columbia University.  "Cancer immunotherapy represents an entirely new era in medicine and patient care."

The exploratory analyses include data from three Phase 3 trials in patients with metastatic castrate resistant prostate cancer (Studies D9901, D9902A, and IMPACT) that were integrated to examine the treatment effect in a larger group of patients, the use of docetaxel before and after randomization, and relationships between certain product parameters and clinical outcome.  These include:

  • A poster presentation by Dr. Celestia Higano, professor of oncology and urology at the University of Washington, titled, "Predictors
    '/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering
2. Dendreon Announces Pricing of Common Stock Offering
3. Dendreon Appoints Hans Bishop as Chief Operating Officer
4. Dendreon Announces Proposed Public Offering of Common Stock
5. Dendreon Receives FDA Acknowledgement of Complete Response
6. Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization
7. Dendreon Completes Submission of Biologics License Application for PROVENGE
8. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
9. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
10. Dendreon Announces Analyst Day Webcast Presentation to be Held on September 24, 2009
11. Dendreon Reports Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... Texas (PRWEB) March 26, 2015 ReliantHeart, ... technologies, and Transonic, a supplier of precision transit-time flow ... that will greatly improve the efficiency of the ... enable LVAD patients to experience greater mobility and peace ... with the miniature flow board, will draw 1/6th of ...
(Date:3/26/2015)... WriteResult, a premier provider of ePRO technologies ... School of Public Health and New Haven Farms to ... month-long project. The goal of the study was to ... free access to fresh produce and nutrition education on ... high blood pressure, diabetes and weight gain. Patients completed ...
(Date:3/25/2015)... March 25, 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or ... a result of recent discussions with certain shareholders representing ... the Company, after dealing with certain matters including the ... of shareholders on March 26, 2015 (the "Meeting") it ... of directors will take place when the Meeting reconvenes. ...
(Date:3/25/2015)... NEW YORK , March 25, 2015 /PRNewswire/ ... has commenced Factual Stock Report coverage on ... Bioceuticals (OTCQX: ATTBF; CSE: ATT): is a specialty ... subsidiaries of cultivating, licensing and marketing proprietary ingredients, ... medicinal markets in North America ...
Breaking Biology Technology:LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 3Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 2Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 3SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 2SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 3SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 4SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 5S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 5
... the cleanest, greenest and far and away most abundant ... woefully under-utilized. High costs have been a major deterrant ... - densely packed nanoscale arrays of optically active semiconductors ... of relatively cheap and scalable solar cells, but have ...
... 17, 2010 Nanotrope, Inc. announced today that it ... ground-breaking diagnostic test for influenza and other viral infections. ... an artificial "cell" engineered with specific membrane compositions and ... mimic as it would a normal host cell.  Once ...
... American Heart Association Late Breaker Session ... ... lpUnit=,PRN,; --> ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var ...
Cached Biology Technology:A new twist for nanopillar light collectors 2A new twist for nanopillar light collectors 3Nanotrope, Inc. Receives Patent on New Diagnostic Test for Influenza and Other Viral Infections 2Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 2Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 3Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 4Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 5Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 6Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 7Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 8Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 9Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 10
(Date:3/10/2015)... Utah , March 10, 2015   Tute ... interpretation, has been selected by next-generation sequencing company ... of whole exome and targeted gene panel interpretation. ... provider, has adopted the most current technologies to support ... genetic research. The company offers two types of exome ...
(Date:3/4/2015)... 04, 2015 Research and Markets ... the "Global Biometrics Market Forecast and Opportunities, ... The market for biometric authentication systems is projected ... till 2020 The driving forces for ... needs, government projects and constant development in technology. ...
(Date:3/2/2015)... , March 2, 2015  Businesses have a ... protection company Tharon Rankins Enterprises has announced the ... an ultra-safe way for businesses to protect their ... transactions. Beconux is a biometric ... Enterprises. Functioning similarly to an ATM machine, the ...
Breaking Biology News(10 mins):PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 3Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3Personal Data Protection Company Launches New Product 2
... Putnam Valley, NY. (Dec. 18, 2013) ... therapy for acute liver failure, either for liver ... However, maintaining the viability and functional aspects of ... freezing (cryopreservation). In an effort to improve both ...
... Institute of Science and Technology (UNIST) announced a method ... which led to the fabrication of a graphene-based field ... opportunities for practical use in electronic devices. ... research team led by Prof. Jong-Beom Baek have discovered ...
... Cell biologists at the Ruhr-Universitt Bochum (RUB) have launched ... enzyme Parkin in promoting neuronal survival. The team of ... Physiological Chemistry, Department of Molecular Cell Biology, is looking ... Michael J. Fox Foundation finances this research project with ...
Cached Biology News:Liver cells benefit from mesenchymal stem cell co-culture prior to transplantation 2UNIST research team opens graphene band-gap 2
Experion Pro260 chips are the microfluidic chips used to perform protein analysis with the Experion automated electrophoresis system. Each chip has the capacity to run 10 protein samples. Supplied as...
... reagents and supplies, for 10 chips, ... to perform protein analysis with 10 ... system. Supplied are 3 x 520 ... stain, 60 microliters Pro260 ladder (10-260 ...
... LabChip 3000 drug discovery system miniaturizes, ... assays. Using LabChip technology, the ... a serial, continuous flow fashion. LabChip ... of results exceeds what is achievable ...
... fast and reliable automation for today's ... development laboratories. Staccato Mini-Workstations offer the ... basic liquid handling and material management ... either Caliper's time proven CLARA™ assay ...
Biology Products: